Herpes Simplex: What the Blister Reveals — and What It Does Not

HSV-1 and HSV-2 are types, not locations

HSV-1 is traditionally associated with cold sores and HSV-2 with genital herpes, but that shorthand is no longer reliable. Oral sex can transmit HSV-1 to the genitals, where it is now a major cause of first-episode genital herpes in many populations. HSV-2 can infect the oral region, although it recurs and sheds there less often.

The type matters because natural history differs by site. Genital HSV-2 generally recurs and sheds more often than genital HSV-1. A person with genital HSV-1 may have a dramatic first episode and then few or no recurrences. A swab that identifies the viral type therefore provides more useful forecasting than lesion location alone.

Globally, HSV is exceptionally common. World Health Organization estimates indicate that billions of people under 50 carry HSV-1 and hundreds of millions of people aged 15–49 carry HSV-2. Most do not know it. Prevalence is evidence of successful human transmission, not evidence that every infected person is ill.

What latency actually means

During an initial infection, HSV replicates in epithelial cells at the contact site. Some particles enter sensory nerve endings and move inward by retrograde axonal transport. Oral infections commonly establish latency in trigeminal ganglia; genital infections commonly use sacral dorsal-root ganglia. Inside the neuronal nucleus, viral DNA persists mainly as a circular episome rather than integrating into human chromosomes.

Latency is active restraint, not disappearance. Most viral genes are silenced while latency-associated transcripts, chromatin state, local immune surveillance, and neuronal signals help maintain the quiet state. When that balance shifts, HSV can resume gene expression, assemble particles, and travel outward by anterograde transport. The result may be a visible lesion, subtle symptoms, or asymptomatic shedding.

This mechanism was not invented to rescue a failed experiment in 1921. Modern evidence includes recovery of HSV DNA and latency-associated transcripts from human sensory ganglia, direct visualization and culture of reactivated virus, animal models that reproduce neural latency, and genome sequencing that links transmitted infections.

The triggers are real — and fully compatible with virology

Commonly reported triggers include:

• febrile illness or another infection;
• psychological stress and sleep disruption;
• intense ultraviolet exposure, especially for oral HSV-1;
• menstruation or other hormonal shifts in some people;
• local friction, dental work, surgery, or tissue injury;
• systemic corticosteroids, chemotherapy, transplantation, HIV, or other immune suppression.

These triggers do not mean the lesion is eliminating stress hormones, mercury, medications, or metabolic waste. They change neuronal signaling, local immunity, inflammatory mediators, and viral gene regulation. Contact with another person belongs to the acquisition story; internal triggers belong to the reactivation story. A recurrent outbreak does not require a new exposure because the established infection is already latent in sensory neurons.

Transmission without panic

HSV spreads through direct contact with infected oral or genital skin, mucosa, secretions, or lesions. Transmission is most likely during an active outbreak and can begin during prodromal tingling, burning, or tenderness. It can also occur when skin looks normal because shedding is intermittent.

Practical risk reduction is layered:

1. Avoid kissing, oral sex, genital contact, and contact with lesions from the first prodromal sign until the area is fully healed.
2. Use condoms or internal condoms consistently; they reduce risk but do not cover every shedding site.
3. Consider daily suppressive therapy when recurrences are frequent, distressing, or when reducing partner risk is a priority.
4. Tell a partner before exposure in a calm, factual way so both people can make an informed decision.
5. Do not touch a lesion and then touch the eye; wash hands after applying topical treatment.

For genital HSV-2 in discordant heterosexual couples, once-daily valacyclovir reduced overall transmission in a randomized trial when combined with counseling and safer-sex measures. It did not make transmission impossible.

Testing: match the test to the question

Fresh lesion: PCR/NAAT is preferred. A swab from a new blister, ulcer, or moist lesion can detect viral DNA and distinguish HSV-1 from HSV-2. Sensitivity falls as lesions crust and heal. Viral culture is highly specific but less sensitive, especially for recurrent or older lesions.

No lesion: type-specific IgG can answer a narrower question. Blood testing can show prior immune recognition of HSV-1 or HSV-2. It cannot identify when infection occurred or whether HSV-1 is oral or genital. Antibodies may take weeks to develop, so testing too soon after exposure can be falsely negative.

HSV-2 enzyme immunoassays can be falsely positive at low index values. CDC guidance recommends confirmation with a second method such as Biokit or Western blot when the initial result is low-positive. HSV IgM is not recommended: it is not reliably type-specific and can become positive during recurrences.

Routine blood screening of every asymptomatic adult is not recommended in the United States because false positives and psychosocial harms can outweigh benefit in low-risk populations. Testing is more useful when genital symptoms are unexplained, a partner has genital herpes, or clinical history makes the result actionable.

Treatment is a choice, not an automatic lifetime sentence

Acyclovir, valacyclovir, and famciclovir block viral DNA replication. They do not remove latent HSV from neurons, but decades of use and randomized trials show that they reduce symptoms, lesion duration, viral shedding, and recurrences.

First recognized genital episode. Antiviral treatment is generally recommended because initial disease can be prolonged or severe.

Episodic treatment. Medication begins at prodrome or within the first day of lesions. This suits people with infrequent outbreaks who can recognize the onset quickly.

Suppressive treatment. Daily medication is reasonable for frequent or severe recurrences, major anxiety or disruption, or transmission reduction. It lowers recurrence frequency by roughly 70–80% among people with frequent outbreaks, and many experience no symptomatic recurrences while taking it. The need should be revisited periodically because recurrence rates often decline over time.

Long-term daily therapy is not mandatory for every person with HSV. It is also not an unstudied experiment limited to one year: clinical experience, surveillance, and long-duration use support safety in immunocompetent people. Headache and nausea are among the more common effects. Kidney injury and neurotoxicity are uncommon but important, especially with dehydration, kidney impairment, older age, or excessive dosing; dose adjustment may be needed. Antiviral resistance remains rare in immunocompetent people and is more relevant with substantial immune suppression.

A no-shame disclosure framework

A useful disclosure is brief and specific: “I carry genital HSV-[type]. I avoid contact during symptoms, and we can use barriers and/or suppression to lower risk. It is common and manageable, but the risk is not zero.”

A diagnosis cannot establish when transmission occurred or who transmitted it. HSV may remain unnoticed for months or years, and blood testing does not date infection. An outbreak is not proof of recent infidelity. Shame drives secrecy and avoidance of care; accurate risk language improves both.

Situations that need prompt care

Seek urgent assessment for eye pain, light sensitivity, a red eye with blurred vision, or lesions near the eye; HSV keratitis can threaten sight, and steroid eye drops can worsen epithelial disease if used without specialist direction.

Emergency evaluation is warranted for severe headache with fever, confusion, altered behavior, seizures, or focal neurologic symptoms because HSV encephalitis is rare but life-threatening. Extensive lesions, inability to urinate, severe pain, dehydration, eczema with rapidly spreading blisters, or disease in a significantly immunocompromised person also need prompt care.

Pregnancy deserves specific planning. The greatest neonatal risk occurs when genital HSV is first acquired late in pregnancy because protective maternal antibodies have not had time to develop. Anyone pregnant with new genital lesions, a partner with HSV, or possible recent exposure should contact their obstetric team promptly. Active lesions or prodrome at labor change delivery management; this is not a setting for self-treatment.